Novartis' Ultibro boosts lung function in COPD study; AbbVie nabs orphan tag for Humira in eye disease;

@FiercePharma: Top-read on FP Tues: How did AstraZeneca make the Pfizer bid a Harry vs. Voldemort story? Article | Follow @FiercePharma

@TracyStaton: Some $AZN investors are balking at the board's $PFE snub. Others are practically high-fiving Chairman Johannson. More from Reuters | Follow @TracyStaton

@EricPFierce: warning letter ravages Sun Pharma's data deletion methods at plant in Gujarat. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Should FDA allow drug ads to include price comparisons? A planned study aims to find out. FiercePharmaMarketing story | Follow @CarlyHFierce

> Novartis ($NVS) said a study showed its new respiratory drug Ultibro Breezhaler beat a combination of tiotropium and formoterol therapy at improving lung function in patients with chronic obstructive pulmonary disease. Release

> AbbVie ($ABBV) won an orphan designation for its megablockbuster anti-inflammatory drug Humira as a treatment for a rare inflammatory disease of the eye. Release

> Amphastar Pharmaceuticals filed for an initial public offering of up to $100 million to help expand its drug portfolio. Report (sub. req.)

> Merck Animal Health said its chewable table for flea and tick control, Bravecto, won FDA approval. Release

Medical Device News

@FierceMedDev: Efforts to repeal device tax stall ahead of Memorial Day break. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: PwC says be on the lookout for 'transformational' med tech deals. Report | Follow @VarunSaxena2

@MichaelGFierce: UC Davis team isolates fungus enzyme to cross blood-brain barrier. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: ICYMI yesterday: Medtronic and Edwards Lifesciences settle the score in ongoing patent feud. Article | Follow @EmilyWFierce

> Medtronic eyes peel-and-stick sensor company with a $150M deal. Story

> CareFusion runs into more 'deadly' trouble with infusion pump. News

> Medtronic wins a CE mark for its NC Euphora balloon catheter. Story

Biotech News

@FierceBiotech: ICYMI yesterday: Angry $AZN investors may hold the only key to a $PFE deal. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: You ever notice how a statement from Big Pharma often sounds like it came from the Death Star? And they wonder why they have such a bad rep. | Follow @JohnCFierce

@DamianFierce: Takeda's IBD drug vedolizumab wins FDA approval, will sell as Entyvio. Report | Follow @DamianFierce

@EmilyMFierce: Animal model that mimics hep B, C in humans could spur new treatments. FierceBiotech Research story | Follow @EmilyMFierce

> Swelling ranks of AstraZeneca's dissident shareholders press for a Pfizer deal. Story

> AstraZeneca partner Ardelyx pitches $69M IPO. Item

> Shire heads to the FDA with its dry eye drug despite a so-so PhIII. Article

> Gene therapy upstart bags a $22M A round for neurodegenerative work. News

Drug Delivery News

> Stem cells loaded with herpesvirus attack glioblastoma brain tumors in mice. Story

> Phosphagenics' animal health topical patch shows promise. Story

> Smallest, fastest nanomotor moves drugs and releases them on demand. More

> New data boost Insmed's inhaled liposomal delivery mechanism for lung infections. Article

> Reckitt Benckiser to develop nasal spray for emergency overdose of opioids. Report

Diagnostics News

> KineMed, CHDI extend their Huntington's biomarker development deal. News

> Blood Dx shows promise helping women to predict premature labor. Report

> German researchers tie CTC presence to breast cancer survival odds. More

> Water Street bets on German specialty Dx outfit. Article

> U.K.'s Enigma Diagnostics jumps into China with disease pathogen testing. Story

Pharma Marketing News

> Top payer group shoots down Gilead's hep C drug Sovaldi on price. Item

> Novo preps for FDA panel hearing on lucrative obesity use for liraglutide. Story

> FDA weighs the free-speech case for off-label marketing. Report

> Allergan's pipeline in a drug, Botox could keep new marketing twists coming. Article

And Finally... Mice run for fun, not just work, research shows. Report

Suggested Articles

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.